Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

doi:10.1158/1078-0432.CCR-17-3431

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2018

Tanioka Maki, Fan Cheng, Parker Joel S, Hoadley Katherine A, Hu Zhiyuan, Li Yan, Hyslop Terry M, Pitcher Brandelyn N, Soloway Matthew G, Spears Patricia A, Henry Lynn N, Tolaney Sara, Dang Chau T, Krop Ian E, Harris Lyndsay N, Berry Donald A, Mardis Elaine R, Winer Eric P, Hudis Clifford A, Carey Lisa A, Perou Charles M

Abstract excerpt

Purpose: Response to a complex trastuzumab-based regimen is affected by multiple features of the tumor and its microenvironment. Developing a predictive algorithm is key to optimizing HER2-targeting therapy.Experimental Design: We analyzed 137 pretreatment tumors with mRNA-seq and DNA exome sequencing from CALGB 40601, a neoadjuvant phase III trial of paclitaxel plus trastuzumab with or without lapatinib in stage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to DNA Copy Number Variations

Share to Drug Resistance, Neoplasm

Share to Neoadjuvant Therapy

Share to Receptor, ErbB-2

Share to Transcriptome

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 30037817
DOI: 10.1158/1078-0432.CCR-17-3431
PMCID: PMC6214737

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.PMID 30037817Read ↗

Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasetsSemantic proximity Read ↗

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Semantic proximity Read ↗

Relationship Between Gene Expression and Drug Response in Triple-Negative Breast Cancer: Leveraging Single-Cell RNA Sequencing and Machine Learning to Identify Biomarker ProfilesSemantic proximity Read ↗

Retrospective multi-cohort validation of a real-world transcriptomics-guided machine learning model for treatment response prediction in breast cancerSemantic proximity Read ↗

Genetic determinants of the molecular portraits of epithelial cancers.Semantic proximity Read ↗

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerSemantic proximity Read ↗

Systematic identification of non-coding pharmacogenomic landscape in cancer.Semantic proximity Read ↗

A machine learning framework for supervised treatment response prediction from tumor transcriptomics: A large-scale pan-cancer studySemantic proximity Read ↗

DNA-Based Deep Learning and Association Studies for Drug Response Prediction in LeiomyosarcomaSemantic proximity Read ↗

Deep Learning on Histopathological Images to Predict Breast Cancer Recurrence Risk and Chemotherapy BenefitSemantic proximity Read ↗

Machine learning-informed liquid-liquid phase separation for personalized breast cancer treatment assessment.Semantic proximity Read ↗

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.